US FDA revokes EIR issued to Aurobindo Pharma's Unit IV facility

The US Food and Drug Administration (US FDA) on Friday revoked the Establishment Inspection Report(EIR) issued on February 18 for Aurobindo Pharma Limited's Unit IV injectable formulations unit.

Feb 21, 2020 06:02 IST Source : Business Standard

Aurobindo Pharma
The US Food and Drug Administration (US FDA) on Friday revoked the Establishment Inspection Report(EIR) issued on February 18 for Aurobindo Pharma Limited's Unit IV injectable formulations unit.

Related Story